Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | CTSK | P43235 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.33 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.33 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.33 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.32 |
| ▸ | GFER | P55789 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1338889 | 0.81 | — | — | |
| SCHEMBL12941126 | 0.76 | ALOX15 (0.33) | SMN1; SMN2ALOX15KDM4EHTTHPGD | |
| SCHEMBL20345780 | 0.75 | SMN1; SMN2 (0.48) | SMN1; SMN2ALOX15KDM4ECYP2C19LMNA | |
| SCHEMBL9711726 | 0.72 | — | — | |
| SCHEMBL304534 | 0.71 | SMN1; SMN2 (0.45) | SMN1; SMN2ALOX15KDM4ECYP2C19LMNA | |
| SCHEMBL428835 | 0.70 | — | — | |
| SCHEMBL16268624 | 0.70 | NPSR1 (0.41) | KDM4ECYP2C19LMNATSHRNPSR1 | |
| SCHEMBL30761090 | 0.69 | KDM4E (0.31) | KDM4ECYP2C19LMNA | |
| SCHEMBL20987665 | 0.69 | CRBN (0.33) | CTSK | |
| SCHEMBL38953 | 0.67 | SMN1; SMN2 (0.56) | SMN1; SMN2ALOX15KDM4ECYP2C19LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4727647-A1 | GLYCOGEN SYNTHASE KINASE 3 INHIBITORS AND USES THEREOF | The Broad Institute Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20260103465-A1 | GLYCOGEN SYNTHASE KINASE 3 INHIBITORS AND USES THEREOF | THE BROAD INSTITUTE, INC. (US) | 2026-04-16 | — | — | US | disclosed |
| US-20250313563-A1 | GLYCOGEN SYNTHASE KINASE 3 INHIBITORS AND USES THEREOF | THE BROAD INSTITUTE, INC. (US) | 2025-10-09 | — | — | US | disclosed |
| EP-4601637-A2 | GLYCOGEN SYNTHASE KINASE 3 INHIBITORS AND USES THEREOF | The Broad Institute Inc. (US) | 2025-08-20 | — | — | EP | disclosed |
| US-12227501-B2 | 3-amino-2-[2-(acylamino)pyridin-4-yl]-1,5,6,7-tetrahydro-4h-pyrrolo[3,2-c]pyridin-4-one as CSNK1 inhibitors | BAYER AKTIENGESELLSCHAFT (DE) | 2025-02-18 | — | — | US | disclosed |
| WO-2024259178-A1 | GLYCOGEN SYNTHASE KINASE 3 INHIBITORS AND USES THEREOF | THE BROAD INSTITUTE, INC. (US) | 2024-12-19 | — | — | WO | disclosed |
| EP-4188551-B1 | ARYL SUBSTITUTED PYRROLO-PYRIDINONES AND THERAPEUTIC USES THEREOF | BAYER AG (DE) | 2024-12-18 | — | — | EP | disclosed |
| WO-2024081939-A2 | GLYCOGEN SYNTHASE KINASE 3 INHIBITORS AND USES THEREOF | THE BROAD INSTITUTE, INC. (US) | 2024-04-18 | — | — | WO | disclosed |
| US-20230416249-A1 | N-[2-({4-[3-(ANILINO)-4-OXO-4,5,6,7-TETRAHYDRO-1H-PYRROLO[3,2-C]PYRIDIN-2-YL]PYRIDIN-3-YL)OXY)ETHYL]PROP-2-ENAMIDE DERIVATIVES AND SIMILAR COMPOUNDS AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER | BAYER AKTIENGESELLSCHAFT (DE) | 2023-12-28 | — | — | US | disclosed |
| US-20230322767-A1 | ARYL SUBSTITUTED PYRROLO-PYRIDINONES AND THERAPEUTIC USES THEREOF | THE BROAD INSTITUTE, INC. | 2023-10-12 | — | — | US | disclosed |
| EP-1660085-A1 | PYRIDYLPYRROLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | Pharmacia Italia S.p.A. (IT) | 2006-05-31 | — | — | EP | disclosed |
| EP-1660475-A1 | PYRIMIDYLPYRROLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | Pharmacia Italia S.p.A. (IT) | 2006-05-31 | — | — | EP | disclosed |
| US-20050043323-A1 | Pyrimidylpyrrole derivatives active as kinase inhibitors | PHARMACIA ITALIA S.P.A. (IT) | 2005-02-24 | — | — | US | disclosed |
| US-20050043346-A1 | Pyridylpyrrole derivatives active as kinase inhibitors | PHARMACIA ITALIA S.P.A. (IT) | 2005-02-24 | — | — | US | disclosed |
| WO-2005014572-A1 | PYRIMIDYLPYRROLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | PHARMACIA ITALIA S.P.A. (IT) | 2005-02-17 | — | — | WO | disclosed |
| WO-2005013986-A1 | PYRIDYLPYRROLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | PHARMACIA ITALIA S.P.A. (IT) | 2005-02-17 | — | — | WO | disclosed |
| US-5114461-A | Herbicides | MAY & BAKER LIMITED (GB) | 1992-05-19 | — | — | US | disclosed |
| EP-0354047-A2 | Herbicidal method using atrazine | MAY & BAKER LIMITED (GB) | 1990-02-07 | — | — | EP | disclosed |
| EP-0354046-A2 | Herbicidal method using bromoxynil | MAY & BAKER LIMITED (GB) | 1990-02-07 | — | — | EP | disclosed |
| EP-0278742-A2 | Cyclic diones | MAY & BAKER LIMITED (GB) | 1988-08-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043346-A1 | Pyridylpyrrole derivatives active as kinase inhibitors | MAP3K6, MAP3K5, MAP4K2 | SMN1; SMN2 2469/4885ALOX15 4632/4885KDM4E 803/4885 |
| US-20230416249-A1 | N-[2-({4-[3-(ANILINO)-4-OXO-4,5,6,7-TETRAHYDRO-1H-PYRROLO[3,2-C]PYRIDIN-2-YL]PYRIDIN-3-YL)OXY)ETHYL]PROP-2-ENAMIDE DERIVATIVES AND SIMILAR COMPOUNDS AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER | EGFR, ERBB2, ERBB4 | SMN1; SMN2 4251/4885ALOX15 2341/4885KDM4E 1584/4885 |
| US-20050043323-A1 | Pyrimidylpyrrole derivatives active as kinase inhibitors | TYMP, DTYMK, DCK | SMN1; SMN2 2627/4885ALOX15 3563/4885KDM4E 959/4885 |
| US-20250313563-A1 | GLYCOGEN SYNTHASE KINASE 3 INHIBITORS AND USES THEREOF | GSK3B, GSK3A, PYGL | SMN1; SMN2 1989/4885ALOX15 4148/4885KDM4E 3321/4885 |
| US-20230322767-A1 | ARYL SUBSTITUTED PYRROLO-PYRIDINONES AND THERAPEUTIC USES THEREOF | PNPO, THPO, PAH | SMN1; SMN2 380/4885ALOX15 723/4885KDM4E 2737/4885 |
| US-12227501-B2 | 3-amino-2-[2-(acylamino)pyridin-4-yl]-1,5,6,7-tetrahydro-4h-pyrrolo[3,2-c]pyridin-4-one as CSNK1 inhibitors | CSNK1A1, CSNK1G1, CSNK1E | SMN1; SMN2 2465/4885ALOX15 4017/4885KDM4E 1370/4885 |
| US-20260103465-A1 | GLYCOGEN SYNTHASE KINASE 3 INHIBITORS AND USES THEREOF | GSK3A, GSK3B, GYS2 | SMN1; SMN2 1126/4885ALOX15 4106/4885KDM4E 4634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.